Keyphrases
Parkinson's Disease
100%
Glycopeptides
100%
Pituitary Adenylate Cyclase-activating Polypeptide (PACAP)
100%
Neuroprotective Therapy
100%
Vasoactive Intestinal Peptide
100%
Growth Factors
66%
Parkinson's Disease Model
50%
Disease Process
50%
Dopaminergic Neurons
33%
Neuroprotection
33%
Dopamine
33%
Blood-brain Barrier
33%
Human Use
16%
Drug Development
16%
Inflammation
16%
Direct Measurement
16%
Neurorestorative
16%
Immunomodulation
16%
Drug Candidates
16%
Further Development
16%
Neuronal Survival
16%
Underlying Disease
16%
Cause of Disease
16%
Systemic Administration
16%
Gunshot
16%
CHO Cells
16%
Brain Levels
16%
Multiple Collisions
16%
Brain Cells
16%
Neurorestoration
16%
Technology Platform
16%
Neuroprotective
16%
Rodent Models
16%
Enhanced Stability
16%
Surfactant
16%
Mass Spectroscopy
16%
Clinical Application
16%
Neuron Death
16%
Clinical Trials
16%
VPAC2 Receptor
16%
Current Therapies
16%
Collision-induced Fragmentation
16%
Human Trials
16%
PAC1 Receptor
16%
Extended Half-life
16%
Drug Stability
16%
Secretin
16%
VPAC1 Receptors
16%
Neurodegenerative Diseases
16%
Microdialysis
16%
Neuroscience
Vasoactive Intestinal Peptide
100%
Neuroprotective Agent
100%
Hypophysis Adenylate Cyclase Activating Polypeptide
100%
Agonist
100%
Parkinson's Disease
100%
Glycopeptide
100%
Growth Factor
50%
In Vivo
25%
Neuroprotection
25%
Dopaminergic Neuron
25%
Blood Brain Barrier
25%
Microdialysis
12%
Surfactant
12%
Vasoactive Intestinal Polypeptide Receptor 1
12%
Spectrometer
12%
Vasoactive Intestinal Polypeptide Receptor 2
12%
Eicosanoid Receptor
12%
Secretin
12%
Neurodegenerative Disorder
12%
Treatment of Parkinson's Disease
12%
Pharmacology, Toxicology and Pharmaceutical Science
Vasoactive Intestinal Polypeptide
100%
Neuroprotective Agent
100%
Parkinson's Disease
100%
Glycopeptide
100%
Hypophysis Adenylate Cyclase Activating Polypeptide
100%
Disease
44%
Growth Factor
44%
Neuroprotection
22%
Dopamine Receptor Stimulating Agent
22%
Blood-Brain Barrier
22%
Vasoactive Intestinal Polypeptide Receptor 2
11%
Inflammation
11%
Clinical Trial
11%
Drug Stability
11%
Microdialysis
11%
Surfactant
11%
Immunomodulation
11%
Secretin
11%
Systemic Administration
11%
Drug Development
11%
Symptom
11%
Receptor
11%
Vasoactive Intestinal Polypeptide Receptor 1
11%